Trimurthi
60.00
-1.29(-2.10%)
Market Cap₹58.93 Cr
PE Ratio-
IndustryRetail
Company Performance:
1D-2.10%
1M-5.72%
6M+104.57%
1Y+125.48%
5Y+125.48%
View Company Insightsright
More news about Trimurthi
21Sept 25
Novelix Pharmaceuticals Appoints New Directors and Secretarial Auditor
Trimurthi Limited, a Hyderabad-based pharmaceutical company, held its 31st Annual General Meeting on September 19, 2025. The company appointed two new directors: Mr. Gattu Gnana Prakash as Non-Executive Non-Independent Director and Ms. Mayuri Baidya as Non-Executive Independent Director. M/s Khushbu Kanwar & Co. was appointed as the Secretarial Auditor for a five-year term. All resolutions, including new appointments and corporate actions, were passed with overwhelming majority. Other approved actions include adopting financial statements, re-appointing a director, increasing borrowing limits, and authorizing various financial transactions.
11Aug 25
Novelis Reports 36% Drop in Q1 Net Income Despite 13% Sales Growth
Trimurthi, a Hindalco Industries subsidiary, reported mixed Q1 financial results. Net sales increased 13% to $4.70 billion, while net income fell 36% to $96.00 million. Rolled product shipments grew 1% to 963 kilotonnes. Adjusted EBITDA decreased 17% to $416.00 million, but operating cash flow improved 42% to $105.00 million. Higher aluminum prices boosted sales, but profitability was impacted by restructuring charges, higher scrap prices, unfavorable product mix, and negative tariff effects. Capital expenditures totaled $386.00 million, mainly for the new Bay Minette, Alabama plant. The company maintained strong liquidity at $3.00 billion with a net leverage ratio of 3.2x. CEO Steve Fisher noted strong demand for beverage packaging amid headwinds from higher scrap prices.
Trimurthi
60.00
-1.29
(-2.10%)
1 Year Returns:+125.48%
Industry Peers
Vijaypd Ceutical
44.40
(-1.33%)
Trimurthi
60.00
(-2.10%)